Current progress, challenges and future prospects of indazoles as protein kinase inhibitors for the treatment of cancer. Issue 41 (20th July 2021)

• Record Type: Journal Article
• Authors: Tandon, Nitin; Luxami, Vijay; Kant, Divya; Tandon, Runjhun; Paul, Kamaldeep
• Is Part Of: RSC advances. Volume 11:Issue 41(2021)
• Page Start: 25228
• Page End: 25257
• Publication Date: 2021-07-20
• Subjects: Chemistry -- Periodicals; 540.5
• DOI: 10.1039/d1ra03979b
• Languages: English
• ISSNs: 2046-2069

Abstract

Abstract : The indazole core is an interesting pharmacophore due to its applications in medicinal chemistry. Abstract : The indazole core is an interesting pharmacophore due to its applications in medicinal chemistry. In the past few years, this moiety has been used for the synthesis of kinase inhibitors. Many researchers have demonstrated the use of indazole derivatives as specific kinase inhibitors, including tyrosine kinase and serine/threonine kinases. A number of anticancer drugs with an indazole core are commercially available, e.g. axitinib, linifanib, niraparib, and pazopanib. Indazole derivatives are applied for the targeted treatment of lung, breast, colon, and prostate cancers. In this review, we compile the current development of indazole derivatives as kinase inhibitors and their application as anticancer agents in the past five years.